Top-Rated StocksTop-RatedPositive News SentimentPositive NewsNASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $57.48 +1.44 (+2.57%) Closing price 04:00 PM EasternExtended Trading$57.48 +0.01 (+0.01%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protagonist Therapeutics Stock (NASDAQ:PTGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PTGX alerts:Sign Up Key Stats Today's Range$56.10▼$57.7250-Day Range$49.70▼$57.4852-Week Range$33.31▼$60.60Volume470,129 shsAverage Volume605,768 shsMarket Capitalization$3.58 billionP/E Ratio82.12Dividend YieldN/APrice Target$67.20Consensus RatingBuy Company Overview Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Read More Protagonist Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScorePTGX MarketRank™: Protagonist Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 731st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Protagonist Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.43 to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is 82.12, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is 82.12, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.10.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 5.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.74% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Protagonist Therapeutics has recently decreased by 6.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.74% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Protagonist Therapeutics has recently decreased by 6.80%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment1.68 News SentimentProtagonist Therapeutics has a news sentiment score of 1.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Protagonist Therapeutics this week, compared to 6 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,020,877.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Stock News HeadlinesInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 10,415 Shares of StockJuly 29, 2025 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells $705,444.74 in StockJuly 24, 2025 | insidertrades.comCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 22 at 2:00 AM | Investors Alley (Ad)Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot?August 12, 2025 | finance.yahoo.comWedbush Issues Optimistic Estimate for PTGX EarningsAugust 12, 2025 | americanbankingnews.com7PTGX : What 4 Analyst Ratings Have To Say About Protagonist...August 8, 2025 | benzinga.comProtagonist Therapeutics files automatic mixed securities shelfAugust 7, 2025 | msn.comProtagonist (PTGX) Q2 Revenue Falls 26%August 7, 2025 | fool.comSee More Headlines PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $38.60 at the beginning of 2025. Since then, PTGX shares have increased by 48.9% and is now trading at $57.48. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its earnings results on Wednesday, August, 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.02. The company had revenue of $5.55 million for the quarter, compared to the consensus estimate of $8.32 million. Protagonist Therapeutics had a net margin of 24.88% and a trailing twelve-month return on equity of 8.12%. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Top institutional investors of Protagonist Therapeutics include BVF Inc. IL (5.16%), State Street Corp (5.16%), Geode Capital Management LLC (2.33%) and Adage Capital Partners GP L.L.C. (1.76%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Arturo Md Molina, Asif Ali and William D Waddill. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY). Company Calendar Last Earnings8/06/2025Today8/22/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTGX CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees120Year Founded2006Price Target and Rating Average Price Target for Protagonist Therapeutics$67.20 High Price Target$80.00 Low Price Target$38.00 Potential Upside/Downside+16.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio82.12 Forward P/E Ratio23.65 P/E GrowthN/ANet Income$275.19 million Net Margins24.88% Pretax Margin25.71% Return on Equity8.12% Return on Assets7.41% Debt Debt-to-Equity RatioN/A Current Ratio16.97 Quick Ratio16.97 Sales & Book Value Annual Sales$434.43 million Price / Sales8.23 Cash Flow$4.63 per share Price / Cash Flow12.41 Book Value$10.74 per share Price / Book5.35Miscellaneous Outstanding Shares62,210,000Free Float59,163,000Market Cap$3.58 billion OptionableOptionable Beta2.33 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:PTGX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.